We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort
Read MoreHide Full Article
Key Takeaways
Resmed's Smart Comfort gets FDA clearance, offering AI-personalized CPAP settings for OSA patients.
Resmed leverages AI and real-world sleep data to improve comfort and adherence in CPAP therapy.
Resmed's Smart Comfort supports clinicians by easing setup, follow-up, and therapy management.
Resmed (RMD - Free Report) has received FDA clearance for Personalized Therapy Comfort Settings (“PTCS”), which will be marketed as Smart Comfort. The company will debut Smart Comfort in early 2026 in a limited U.S. beta version for new users of myAir, Resmed's consumer sleep companion app, paired with a Resmed AirSense 11 device, and will be followed by a broader U.S. rollout to new myAir users later in 2026.
Smart Comfort is part of Resmed’s connected, personalized sleep-health ecosystem, combining AI, cloud-connected Resmed devices and digital tools to help make sleep health more personal and support therapy efficacy.
RMD Stock Outlook Following the News
After the announcement yesterday, shares of Resmed dropped 2.5%, finishing the session at $250.04. Meanwhile, an estimated 61 million U.S. people have obstructive sleep apnea (OSA), a number projected to reach nearly 77 million by 2050. Left untreated, it increases the risk of high blood pressure, heart disease, type 2 diabetes and stroke. CPAP therapy can significantly reduce the risk of death in people with OSA. Resmed’s Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings to help people with OSA start and maintain CPAP therapy. Accordingly, the news should help support a rebound in RMD stock performance.
Resmed presently boasts a market capitalization of $37.44 billion. The Zacks Consensus Estimate for the company’s fiscal 2026 earnings suggests a 13.2% increase. In the trailing four quarters, it delivered an earnings beat of 3%, on average.
More on Resmed’s Smart Comfort
Since CPAP therapy is not one-size-fits-all, tackling common therapy issues, like comfort and mask fit, early can promote long-term adherence. Smart Comfort leverages Resmed’s proprietary machine-learning algorithms, drawing on more than 100 million nights of de-identified, real-world sleep data and user information, such as age, gender and Apnea-Hypopnea Index (AHI), to recommend individualized comfort settings for CPAP therapy delivered by the company’s AirSense 11 devices.
Image Source: Zacks Investment Research
These include settings that help ease users into therapy, adjust how gradually an AirSense 11 increases pressure and reduce pressure on exhale. Smart Comfort was developed with clinical oversight and ethical data use in compliance with privacy laws, considering quality and patient safety at every stage.
The FDA submission was supported by retrospective real-world evidence showing that Resmed AirSense 10 and 11 users whose comfort settings matched Smart Comfort recommendations had higher engagement and sustained therapy adherence compared to those using default settings.
For healthcare providers, Smart Comfort offers a solution to help streamline user setup and follow-up and reduce manual adjustments so that clinicians can devote more attention to clinical decision-making and patient support.
Industry Prospects Favoring RMD
According to Precedence Research, the global sleep apnea device market is valued at $7.11 billion in 2025 and is expected to witness a compound annual growth rate of 7% through 2034. Factors like the rising prevalence of sleep apnea, the rapidly expanding medical device sector and technological advancements are boosting the market’s growth.
Other Developments at Resmed
In September, Resmed launched Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. It partners with clinicians, researchers, policymakers and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions and elevate sleep as a global health priority.
RMD Stock Price Performance
Year to date, Resmed shares have rallied 9.3% compared with the industry’s rise of 3.2%.
Estimates for BrightSpring Health Services’ 2025EPS have increased 5.7% in the past 30 days. Shares of the company have surged 92.3% in the past year compared with the industry’s 1.1% growth. BTSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.1%. In the last reported quarter, it delivered an earnings surprise of 11.1%.
Illumina shares have fallen 9.4% in the past year. Estimates for the company’s 2025 EPS have risen 0.9% to $4.71 in the past 30 days. ILMN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 6.7%. In the last reported quarter, it posted an earnings surprise of 15.5%.
Omnicell shares have dropped 13.9% in the past year. Estimates for the company’s 2025 EPS have increased 8.3% to $1.70 in the past 30 days. OMCL’s earnings topped estimates in each of the trailing four quarters, delivering an average surprise of 38.7%. In the last reported quarter, it posted an earnings surprise of 41.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort
Key Takeaways
Resmed (RMD - Free Report) has received FDA clearance for Personalized Therapy Comfort Settings (“PTCS”), which will be marketed as Smart Comfort. The company will debut Smart Comfort in early 2026 in a limited U.S. beta version for new users of myAir, Resmed's consumer sleep companion app, paired with a Resmed AirSense 11 device, and will be followed by a broader U.S. rollout to new myAir users later in 2026.
Smart Comfort is part of Resmed’s connected, personalized sleep-health ecosystem, combining AI, cloud-connected Resmed devices and digital tools to help make sleep health more personal and support therapy efficacy.
RMD Stock Outlook Following the News
After the announcement yesterday, shares of Resmed dropped 2.5%, finishing the session at $250.04. Meanwhile, an estimated 61 million U.S. people have obstructive sleep apnea (OSA), a number projected to reach nearly 77 million by 2050. Left untreated, it increases the risk of high blood pressure, heart disease, type 2 diabetes and stroke. CPAP therapy can significantly reduce the risk of death in people with OSA. Resmed’s Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings to help people with OSA start and maintain CPAP therapy. Accordingly, the news should help support a rebound in RMD stock performance.
Resmed presently boasts a market capitalization of $37.44 billion. The Zacks Consensus Estimate for the company’s fiscal 2026 earnings suggests a 13.2% increase. In the trailing four quarters, it delivered an earnings beat of 3%, on average.
More on Resmed’s Smart Comfort
Since CPAP therapy is not one-size-fits-all, tackling common therapy issues, like comfort and mask fit, early can promote long-term adherence. Smart Comfort leverages Resmed’s proprietary machine-learning algorithms, drawing on more than 100 million nights of de-identified, real-world sleep data and user information, such as age, gender and Apnea-Hypopnea Index (AHI), to recommend individualized comfort settings for CPAP therapy delivered by the company’s AirSense 11 devices.
Image Source: Zacks Investment Research
These include settings that help ease users into therapy, adjust how gradually an AirSense 11 increases pressure and reduce pressure on exhale. Smart Comfort was developed with clinical oversight and ethical data use in compliance with privacy laws, considering quality and patient safety at every stage.
The FDA submission was supported by retrospective real-world evidence showing that Resmed AirSense 10 and 11 users whose comfort settings matched Smart Comfort recommendations had higher engagement and sustained therapy adherence compared to those using default settings.
For healthcare providers, Smart Comfort offers a solution to help streamline user setup and follow-up and reduce manual adjustments so that clinicians can devote more attention to clinical decision-making and patient support.
Industry Prospects Favoring RMD
According to Precedence Research, the global sleep apnea device market is valued at $7.11 billion in 2025 and is expected to witness a compound annual growth rate of 7% through 2034. Factors like the rising prevalence of sleep apnea, the rapidly expanding medical device sector and technological advancements are boosting the market’s growth.
Other Developments at Resmed
In September, Resmed launched Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. It partners with clinicians, researchers, policymakers and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions and elevate sleep as a global health priority.
RMD Stock Price Performance
Year to date, Resmed shares have rallied 9.3% compared with the industry’s rise of 3.2%.
RMD’s Zacks Rank and Key Picks
Resmed currently carries a Zacks Rank #3 (Hold).
Some other top-ranked stocks in the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Illumina (ILMN - Free Report) and Omnicell (OMCL - Free Report) . While BrightSpring and Illumina eachsport a Zacks Rank #1 (Strong Buy), Omnicell carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for BrightSpring Health Services’ 2025EPS have increased 5.7% in the past 30 days. Shares of the company have surged 92.3% in the past year compared with the industry’s 1.1% growth. BTSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.1%. In the last reported quarter, it delivered an earnings surprise of 11.1%.
Illumina shares have fallen 9.4% in the past year. Estimates for the company’s 2025 EPS have risen 0.9% to $4.71 in the past 30 days. ILMN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 6.7%. In the last reported quarter, it posted an earnings surprise of 15.5%.
Omnicell shares have dropped 13.9% in the past year. Estimates for the company’s 2025 EPS have increased 8.3% to $1.70 in the past 30 days. OMCL’s earnings topped estimates in each of the trailing four quarters, delivering an average surprise of 38.7%. In the last reported quarter, it posted an earnings surprise of 41.7%.